Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric Assenat

Showing results (71-80 of 153) with videos related to

Pageof 16
Sort By:
Journal of Vascular and Interventional Radiology : JVIR|September 16, 2018
Tumor Targeting and Three-Dimensional Voxel-Based Dosimetry to Predict Tumor Response, Toxicity, and Survival after Yttrium-90 Resin Microsphere Radioembolization in Hepatocellular CarcinomaCarole Allimant, Marilyne Kafrouni, Julien Delicque, et al.
BMC Cancer|September 30, 2009
Bevacizumab plus FOLFIRI or FOLFOX in chemotherapy-refractory patients with metastatic colorectal cancer: a retrospective studyAstrid Lièvre, Emmanuelle Samalin, Emmanuel Mitry, et al.
The Oncologist|October 22, 2011
Cetuximab plus FOLFIRINOX (ERBIRINOX) as first-line treatment for unresectable metastatic colorectal cancer: a phase II trialEric Assenat, Francoise Desseigne, Simon Thezenas, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|January 19, 2016
A phase III study evaluating oral glutamine and transforming growth factor-beta 2 on chemotherapy-induced toxicity in patients with digestive neoplasmFaïza Khemissa, Laurent Mineur, Caroline Amsellem, et al.
International Journal of Cancer|September 9, 2010
EGFR and HER3 mRNA expression levels predict distant metastases in locally advanced rectal cancerAlexandre Ho-Pun-Cheung, Eric Assenat, Caroline Bascoul-Mollevi, et al.
The Oncologist|January 15, 2026
The BEVATOMOX phase II trial: raltitrexed/oxaliplatin/bevacizumab vs mFOLFOX6/bevacizumab in 2nd-line metastatic colorectal cancerEmmanuelle Samalin, Hélène Senellart, Simon Thezenas, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|May 16, 2019
Quantitative evaluation of liver metastases density on computed tomography: A new tool to evaluate early response to bevacizumab-containing chemotherapyThibault Mazard, Eric Assenat, Marie Dupuy, et al.
Reports of Practical Oncology and Radiotherapy : Journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology|May 12, 2017
SBRT planning for liver metastases: A focus on immobilization, motion management and planning imaging techniquesOlivier Riou, Carmen Llacer Moscardo, Pascal Fenoglietto, et al.
Annals of Surgical Oncology|August 20, 2013
A randomized phase II trial of three intensified chemotherapy regimens in first-line treatment of colorectal cancer patients with initially unresectable or not optimally resectable liver metastases. The METHEP trialMarc Ychou, Michel Rivoire, Simon Thezenas, et al.
United European Gastroenterology Journal|December 7, 2023
Atezolizumab and bevacizumab for non-resectable or metastatic combined hepatocellular-cholangiocarcinoma: A multicentric retrospective studyElia Gigante, Mohamed Bouattour, José Ursic Bedoya, et al.
Pageof 16

Showing results (71-80 of 153) with videos related to

Sort By:
Pageof 16
Journal of Vascular and Interventional Radiology : JVIR|September 16, 2018
Tumor Targeting and Three-Dimensional Voxel-Based Dosimetry to Predict Tumor Response, Toxicity, and Survival after Yttrium-90 Resin Microsphere Radioembolization in Hepatocellular CarcinomaCarole Allimant, Marilyne Kafrouni, Julien Delicque, et al.
BMC Cancer|September 30, 2009
Bevacizumab plus FOLFIRI or FOLFOX in chemotherapy-refractory patients with metastatic colorectal cancer: a retrospective studyAstrid Lièvre, Emmanuelle Samalin, Emmanuel Mitry, et al.
The Oncologist|October 22, 2011
Cetuximab plus FOLFIRINOX (ERBIRINOX) as first-line treatment for unresectable metastatic colorectal cancer: a phase II trialEric Assenat, Francoise Desseigne, Simon Thezenas, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|January 19, 2016
A phase III study evaluating oral glutamine and transforming growth factor-beta 2 on chemotherapy-induced toxicity in patients with digestive neoplasmFaïza Khemissa, Laurent Mineur, Caroline Amsellem, et al.
International Journal of Cancer|September 9, 2010
EGFR and HER3 mRNA expression levels predict distant metastases in locally advanced rectal cancerAlexandre Ho-Pun-Cheung, Eric Assenat, Caroline Bascoul-Mollevi, et al.
The Oncologist|January 15, 2026
The BEVATOMOX phase II trial: raltitrexed/oxaliplatin/bevacizumab vs mFOLFOX6/bevacizumab in 2nd-line metastatic colorectal cancerEmmanuelle Samalin, Hélène Senellart, Simon Thezenas, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|May 16, 2019
Quantitative evaluation of liver metastases density on computed tomography: A new tool to evaluate early response to bevacizumab-containing chemotherapyThibault Mazard, Eric Assenat, Marie Dupuy, et al.
Reports of Practical Oncology and Radiotherapy : Journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology|May 12, 2017
SBRT planning for liver metastases: A focus on immobilization, motion management and planning imaging techniquesOlivier Riou, Carmen Llacer Moscardo, Pascal Fenoglietto, et al.
Annals of Surgical Oncology|August 20, 2013
A randomized phase II trial of three intensified chemotherapy regimens in first-line treatment of colorectal cancer patients with initially unresectable or not optimally resectable liver metastases. The METHEP trialMarc Ychou, Michel Rivoire, Simon Thezenas, et al.
United European Gastroenterology Journal|December 7, 2023
Atezolizumab and bevacizumab for non-resectable or metastatic combined hepatocellular-cholangiocarcinoma: A multicentric retrospective studyElia Gigante, Mohamed Bouattour, José Ursic Bedoya, et al.
Pageof 16